Table 3.
Associations between leptin, ObR, leptin/ObR and different clinicopathological parameters
| Leptin | ObR | |||||
| N | Positive (%) | p-value | Positive (%) | p-value | ||
| Diameter (mm) | 0.061 | 0.137 | ||||
| ≤ 10 mm | 9 | 55.6 | 66.7 | |||
| > 10 mm | 42 | 85.7 | 88.1 | |||
| N | > 0.5 | 0.242 | ||||
| N0 | 19 | 84.2 | 94.7 | |||
| N+ (N > 0) | 33 | 78.8 | 81.8 | |||
| LVI | > 0.5 | 0.473 | ||||
| Negative | 24 | 79.2 | 87.5 | |||
| Positive | 27 | 77.8 | 77.8 | |||
| Menopausal status | > 0.5 | > 0.5 | ||||
| Postmenopausal | 15 | 80.0 | 86.7 | |||
| Premenopausal | 39 | 82.1 | 84.6 | |||
| Histotype | > 0.5 | 0.432 | ||||
| Other | 3 | 66.7 | 66.7 | |||
| Ductal (invasive) | 45 | 80.0 | 84.4 | |||
| Inflammatory | 4 | 100.0 | 100.0 | |||
| Intraductal | 3 | 66.7 | 66.7 | |||
| Lobular (invasive) | 4 | 75.0 | 75.0 | |||
| G | 0.495 | 0.366 | ||||
| G1 | 7 | 85.7 | 100.0 | |||
| G2 | 18 | 88.9 | 88.9 | |||
| G3 | 26 | 73.1 | 76.9 | |||
| Ki-67 | > 0.5 | > 0.5 | ||||
| 0–15% | 33 | 75.8 | 81.8 | |||
| 16–25% | 9 | 88.9 | 88.9 | |||
| 26–100% | 14 | 85.7 | 85.7 | |||
| ER/PgR | > 0.5 | > 0.5 | ||||
| ER-/PgR- | 12 | 75.0 | 83.3 | |||
| ER-/PgR+ | 1 | 100.0 | 100.0 | |||
| ER+/PgR- | 6 | 83.3 | 83.3 | |||
| ER+/PgR+ | 37 | 81.1 | 83.8 | |||
| T | 0.019 | 0.400 | ||||
| pT1 | 20 | 70.0 | 80.0 | |||
| pT2 | 23 | 91.3 | 91.3 | |||
| pT3 | 2 | 0.0 | 50.0 | |||
| pT4 | 8 | 100.0 | 87.5 | |||
| pTx | 1 | 100.0 | 100.0 | |||
| TIS | 3 | 66.7 | 66.7 | |||
| HER2 | 0.342 | 0.306 | ||||
| Negative | 28 | 85.7 | 89.3 | |||
| Positive | 31 | 74.2 | 77.4 | |||
For each level of each clinicopathological variable, the total number (N) of patients is given together with the percentage of subjects positive for leptin or ObR expression. Abbreviations as in Tab. 2.